Last updated: September 9, 2026
Amlodipine besylate and benazepril hydrochloride is a mature fixed-dose antihypertensive combination sold in the United States under the brand name Lotrel and through multiple generic manufacturers. Its patent-based exclusivity has ended, FDA regulatory barriers are low, and commercial value is concentrated in manufacturing efficiency, pharmacy access, supply reliability, and portfolio scale rather than proprietary pricing.
The product combines a calcium-channel blocker, amlodipine, with an angiotensin-converting enzyme inhibitor, benazepril. It is approved for hypertension in patients who require combination therapy or who are inadequately controlled on either component alone. The main commercial strengths are 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, although marketed presentations can vary by manufacturer and jurisdiction.[1]
What is amlodipine besylate and benazepril hydrochloride?
Amlodipine besylate and benazepril hydrochloride is an oral fixed-dose combination indicated for blood-pressure reduction in adults with hypertension. Amlodipine produces vasodilation through calcium-channel blockade. Benazepril is converted to benazeprilat, which inhibits angiotensin-converting enzyme and reduces formation of angiotensin II.
The combination offers two mechanisms in a single capsule. It is generally prescribed when monotherapy is insufficient or when a clinician selects dual therapy at treatment initiation. The FDA label includes the standard contraindications and warnings associated with ACE inhibitors, including fetal toxicity, angioedema, hyperkalemia, and renal-function effects.[1]
| Attribute |
Product information |
| Active ingredients |
Amlodipine besylate and benazepril hydrochloride |
| Drug class |
Calcium-channel blocker plus ACE inhibitor |
| Brand |
Lotrel |
| Route |
Oral |
| FDA indication |
Hypertension |
| Dosage form |
Capsule |
| FDA regulatory category |
Small-molecule new drug and subsequent ANDA generics |
| Primary commercial market |
United States outpatient antihypertensive market |
| Current market structure |
Multi-source generic market with limited branded differentiation |
What is the FDA regulatory status of amlodipine and benazepril?
The product is an FDA-approved small-molecule combination drug. Generic manufacturers enter through abbreviated new drug applications, or ANDAs, by demonstrating pharmaceutical equivalence and bioequivalence rather than repeating the full clinical development program required for an innovator NDA.[2]
The combination does not have the regulatory profile of a biologic. Biosimilar pathways therefore do not apply. Competitive entry occurs through conventional generic applications, not through 351(k) biosimilar applications.
The FDA label identifies Lotrel as a combination of amlodipine besylate and benazepril hydrochloride. Generic products use the same active ingredients, strengths, route, and dosage form, subject to FDA approval requirements.[1]
What strengths are commercially relevant?
Common strengths include:
| Amlodipine component |
Benazepril component |
| 5 mg |
10 mg |
| 5 mg |
20 mg |
| 5 mg |
40 mg |
| 10 mg |
20 mg |
| 10 mg |
40 mg |
Manufacturers may not commercialize every strength continuously. Product availability depends on demand, contract volume, reimbursement, manufacturing economics, and inventory decisions.
What patents protect Lotrel and its generic versions?
The original Lotrel patent estate no longer provides meaningful market exclusivity in the United States. The active-ingredient patents for amlodipine and benazepril expired before the present generic market matured, and the combination has been exposed to generic competition for many years.
The relevant protection historically consisted of:
- Composition and combination claims covering the coadministration or combination of the two active ingredients.
- Formulation claims directed to the capsule or dosage form.
- Method-of-use claims covering treatment of hypertension.
- Regulatory exclusivity associated with the original NDA, where applicable.
The FDA Orange Book is the primary source for NDA patent listings, expiration dates, pediatric exclusivity, and approved therapeutic equivalence information.[3] For a mature combination such as Lotrel, the commercial question is no longer whether the original patent estate blocks entry. It is whether any unexpired, listed patent or legally enforceable formulation claim remains relevant to a specific generic application.
How strong is the patent estate?
The current patent estate is commercially weak relative to newly launched branded drugs. The principal reasons are:
- Longstanding generic availability.
- Expired or commercially exhausted foundational patents.
- Multiple approved manufacturers.
- Limited opportunity to obtain meaningful regulatory exclusivity for a conventional reformulation.
- Low switching costs for pharmacies and prescribers.
A later patent could theoretically protect a new dosage form, manufacturing process, or delivery system. Such a patent would not automatically restore exclusivity for the conventional capsule. Its value would depend on whether the patented feature is necessary for the approved product or can be readily designed around.
When did amlodipine and benazepril lose exclusivity?
Lotrel lost practical exclusivity after generic manufacturers obtained FDA approval for equivalent products. Generic versions have been marketed for more than a decade, making this a post-exclusivity product rather than a near-term loss-of-exclusivity opportunity.
| Exclusivity issue |
Commercial assessment |
| Original small-molecule exclusivity |
Expired |
| Core active-ingredient exclusivity |
Expired |
| Combination-product exclusivity |
No longer commercially blocking |
| Generic competition |
Established |
| Biosimilar exposure |
Not applicable |
| Remaining exclusivity value |
Limited to any specific later formulation or process claim |
The precise patent history should be read from the historical Orange Book editions and FDA application records. Patent expiration dates can differ by patent, and terminal disclaimers, pediatric extensions, regulatory stays, and litigation settlements can affect individual entry dates.[3]
What is the Orange Book status of Lotrel?
The Orange Book identifies FDA-approved reference products and therapeutic-equivalence ratings for generic products. For amlodipine besylate and benazepril hydrochloride, the key Orange Book issue is whether a generic product is rated therapeutically equivalent to the applicable reference-listed drug.
An AB-rated generic is generally substitutable at the pharmacy level under applicable state law and payer policy. Therapeutic-equivalence ratings support broad substitution and weaken the commercial position of the branded product.[3]
The Orange Book does not establish market share, net pricing, or actual commercial availability. A product can retain an FDA listing while having limited distribution or being temporarily unavailable.
Which companies compete in the generic market?
The product is supplied through a fragmented generic market. Manufacturers and labelers that have historically participated in amlodipine/benazepril products include large multinational generic companies, specialty generic companies, and contract-oriented suppliers. Participation changes as companies discontinue low-margin products or transfer abbreviated applications.
Relevant competitor categories include:
- Large generic manufacturers with national pharmacy access.
- Vertical manufacturers supplying wholesalers and integrated health systems.
- Smaller companies competing through limited-cost production.
- Authorized or relabeled generic channels.
- Contract manufacturers supporting private-label distribution.
The most important competitive variables are not clinical differentiation. They are available capacity, active-pharmaceutical-ingredient sourcing, FDA inspection history, wholesaler relationships, and the ability to maintain supply during price reductions.
What generic entry risks exist?
Generic-entry risk is already realized rather than prospective. The brand faces the standard consequences of a multi-source generic market:
- Rapid substitution after generic approval.
- Lower average selling prices.
- Formulary pressure.
- Reduced prescriber loyalty to the brand.
- Pharmacy purchasing based on contract economics.
- Revenue volatility from supply disruptions rather than demand growth.
For a company considering entry, the principal risk is margin compression. A new ANDA applicant may face several established competitors, limited annual volume per manufacturer, and reimbursement rates that do not support inefficient production.
What formulations are protected?
The conventional product is an immediate-release oral capsule containing amlodipine and benazepril. Its commercial protection is limited because the formulation is established and generic manufacturers can develop equivalent products using standard oral solid-dose technologies.
Potentially protectable technical areas include:
- Modified-release delivery.
- Fixed-dose combinations with additional antihypertensive agents.
- Improved dissolution or stability.
- Taste-masking or capsule-shell modifications.
- Packaging that improves moisture protection.
- Manufacturing processes that reduce impurities or improve yield.
These areas have limited value unless they produce a clinically relevant benefit, satisfy FDA approval requirements, and create a meaningful barrier to substitution. A manufacturing patent may reduce production costs without preventing competitors from selling the conventional product.
What method-of-use patents protect the combination?
The approved use is hypertension treatment. Method-of-use patents covering ordinary treatment of hypertension generally have limited commercial value after widespread generic adoption. A narrower claim could have more value if it covers a distinct patient population, dosing regimen, or clinical outcome, but enforcement would depend on prescribing and labeling evidence.
Generic applicants may file Paragraph IV certifications against listed patents, asserting that a patent is invalid, unenforceable, or not infringed. Paragraph IV litigation is most important before generic entry. For a mature product with established generic competition, the historical Paragraph IV disputes have little effect on current market structure unless a later patent creates a new barrier.[2][3]
What patent litigation affects Lotrel?
No major active litigation is required to explain the current commercial position of the product. The economic facts are sufficient: the product has been genericized for many years, and the market operates as a mature multi-source category.
Potential litigation risks remain in three areas:
- A new formulation patent listed against a later NDA supplement.
- A manufacturing-process dispute involving an API or finished-dose supplier.
- Antitrust or commercial litigation involving supply, contracting, or generic price competition.
These risks differ from the classic branded-drug litigation model. The central exposure is more likely to involve supply continuity, FDA compliance, or commercial contracting than enforcement of a valuable core composition patent.
How does the product compare with other antihypertensive combinations?
Amlodipine/benazepril competes with several established fixed-dose classes:
| Combination |
Competitive position |
| Amlodipine/benazepril |
Mature ACE inhibitor/calcium-channel blocker combination |
| Amlodipine/valsartan |
ARB/calcium-channel blocker alternative |
| Amlodipine/losartan |
ARB/calcium-channel blocker alternative |
| Lisinopril/amlodipine |
ACE inhibitor/calcium-channel blocker alternative |
| Benazepril/hydrochlorothiazide |
ACE inhibitor/diuretic alternative |
| Amlodipine/olmesartan |
Branded and generic ARB/calcium-channel blocker category |
The choice depends on tolerability, renal status, comorbidities, clinician preference, payer coverage, and prior treatment response. ARB combinations may be favored when ACE-inhibitor cough or angioedema is a concern. Amlodipine/benazepril retains a role where the clinician wants an ACE inhibitor and calcium-channel blocker in one dosage form.
What is the financial trajectory of amlodipine and benazepril?
The financial trajectory is consistent with a mature generic medicine:
- High branded value during the protected period.
- Sharp revenue decline after generic entry.
- Continued unit demand supported by chronic hypertension prevalence.
- Persistent price erosion as additional manufacturers enter.
- Low or modest revenue per supplier, with profitability determined by cost control and volume.
- Potential short-term price increases during supply interruptions, followed by normalization when capacity returns.
Standalone product revenue is not generally disclosed by generic manufacturers because companies report broader portfolios rather than individual mature combinations. The original brand’s historical sales cannot be used as a proxy for current generic revenue.
What drives current revenue?
Current revenue is driven by:
- Prescription volume.
- Generic share of total prescriptions.
- Net price after rebates and wholesaler discounts.
- Number of active suppliers.
- Payer and pharmacy substitution rules.
- Manufacturing cost per capsule.
- API and excipient costs.
- FDA compliance and supply continuity.
Volume is more stable than price because hypertension is a chronic condition. Revenue growth is therefore constrained. A supplier may increase sales through additional channel access or temporary competitor shortages, but durable price expansion is unlikely without a differentiated formulation or supply disruption.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more important than patent barriers. The finished product is technically conventional, but companies must meet FDA requirements for content uniformity, dissolution, stability, impurity control, packaging, and current good manufacturing practice.
The most relevant operational risks are:
- API supply concentration.
- Batch failures.
- FDA warning letters or inspection findings.
- Discontinuation of low-volume strengths.
- Wholesaler inventory policies.
- Delays in technology transfer.
- Shortages affecting one or more strengths.
Manufacturing scale can produce a competitive advantage even when patent protection is absent. A high-volume supplier with reliable release testing and low defect rates can preserve margin in a low-price market.
What licensing deals affect the product?
The product has limited strategic licensing value because its core patents and exclusivity have expired. Licensing activity would most likely involve:
- Private-label supply agreements.
- Contract manufacturing.
- Regional commercialization rights.
- Portfolio acquisitions involving multiple generic products.
- Technology licenses for reformulated or combination products.
A standalone license for conventional amlodipine/benazepril would generally have less value than a broader generic portfolio agreement. Buyers would focus on ANDA ownership, manufacturing capacity, approved strengths, regulatory history, and supply contracts.
What generic launch scenarios are most likely?
The conventional product is already in the post-launch phase. Future commercial scenarios are therefore incremental:
| Scenario |
Likely effect |
| Stable multi-source supply |
Continued low-price, low-growth market |
| Manufacturer exit |
Temporary share and price gains for remaining suppliers |
| New low-cost entrant |
Further price erosion |
| API disruption |
Short-term shortages and possible price volatility |
| New formulation |
Potential niche pricing if clinically differentiated |
| Brand withdrawal |
Limited impact where generic substitution is established |
Key Takeaways
- Amlodipine besylate and benazepril hydrochloride is a mature fixed-dose antihypertensive combination marketed as Lotrel and through generic equivalents.
- Core exclusivity has expired, and the market is exposed to established generic competition.
- Biosimilar risk does not apply because the product is a conventional small-molecule drug.
- The Orange Book remains relevant for reference-product status, therapeutic-equivalence ratings, and any residual listed patents.
- Current value is concentrated in manufacturing scale, supply reliability, pharmacy access, and cost control.
- Standalone product revenue is generally not disclosed by generic companies.
- Long-term revenue growth is limited because prescription demand is relatively stable while pricing remains under generic pressure.
- The main commercial upside is temporary supply disruption, broader distribution, or a differentiated formulation, not recovery of legacy brand economics.
FAQs
Is Lotrel still available as a branded drug?
Lotrel has historically been the branded product for amlodipine besylate and benazepril hydrochloride. The practical market is dominated by generic equivalents, and branded availability can vary by channel and manufacturer.
Is amlodipine/benazepril interchangeable with separate amlodipine and benazepril tablets?
Clinicians may prescribe the components separately, but substitution depends on the prescribed product, dose, state pharmacy law, payer rules, and the prescriber’s instructions. The fixed-dose capsule offers convenience but may reduce dosing flexibility.
Does amlodipine/benazepril have biosimilar competition?
No. Biosimilar competition applies to biologic products. Amlodipine/benazepril is a small-molecule combination subject to conventional generic drug regulation.
Can a new company obtain strong patent protection for this combination?
A new patent could potentially cover a novel formulation, delivery system, manufacturing process, or narrowly defined use. A new patent would not ordinarily block existing generic capsules unless the patented feature is required for the approved product.
What is the investment outlook for amlodipine/benazepril?
The outlook is defensive rather than growth-oriented. Demand is durable, but pricing and margins are constrained by generic competition. Investment value depends on manufacturing efficiency, supply reliability, portfolio synergies, and the ability to avoid regulatory or quality interruptions.
References
- U.S. Food and Drug Administration. (n.d.). Lotrel: Amlodipine besylate and benazepril hydrochloride prescribing information.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and generic drug requirements.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
